The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Targeting noncoding RNAs in disease
Open accessAbstract
Many RNA species have been identified as important players in the development of chronic diseases, including cancer. Over the past decade, numerous studies have highlighted how regulatory RNAs such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) play crucial roles in the development of a disease state. It is clear that the aberrant expression of miRNAs promotes tumor initiation and progression, is linked with cardiac dysfunction, allows for the improper physiological response in maintaining glucose and insulin levels, and can prevent the appropriate integration of neuronal networks, resulting in neurodegenerative disorders. Because of this, there has been a major effort to therapeutically target these noncoding RNAs. In just the past 5 years, over 100 antisense oligonucleotide-based therapies have been tested in phase I clinical trials, a quarter of which have reached phase II/III. Most notable are fomivirsen and mipomersen, which have received FDA approval to treat cytomegalovirus retinitis and high blood cholesterol, respectively. The continued improvement of innovative RNA modifications and delivery entities, such as nanoparticles, will aid in the development of future RNA-based therapeutics for a broader range of chronic diseases. Here we summarize the latest promises and challenges of targeting noncoding RNAs in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yin, D., He, X., Zhang, E., Kong, R., De, W., & Zhang, Z. (2014) · Medical Oncology · doi:10.1007/s12032-014-0253-8 · Cited by 185
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Self-citation
Cited by
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Self-citationLNCcation: lncRNA localization and function
Bridges, M. C., Daulagala, A. C., & Kourtidis, A. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202009045 · Cited by 1,556
The functions and unique features of long intergenic non-coding RNA
Ransohoff, J. D., Wei, Y., & Khavari, P. A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.104 · Cited by 1,330
Principles for targeting RNA with drug-like small molecules
Warner, K. D., Hajdin, C. E., & Weeks, K. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.93 · Cited by 749
Zhang, J., Liu, H., Hou, L., Wang, G., Zhang, R., Huang, Y., Chen, X., & Zhu, J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0719-3 · Cited by 517
Long non-coding RNAs: From disease code to drug role
Chen, Y., Li, Z., Chen, X., & Zhang, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.001 · Cited by 503
Clinical epigenetics: seizing opportunities for translation
Berdasco, M., & Esteller, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 498
Lu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine · doi:10.1038/nm.4424 · Cited by 425
Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications
Wong, C.-M., Tsang, F. H.-C., & Ng, I. O.-L. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.169 · Cited by 424
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
ncRNA-Encoded Peptides or Proteins and Cancer
Wang, J., Zhu, S., Meng, N., He, Y., Lu, R., & Yan, G.-R. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.001 · Cited by 330
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
Amodio, N., Stamato, M. A., Juli, G., Morelli, E., Fulciniti, M., Manzoni, M., Taiana, E., Agnelli, L., Cantafio, M. E. G., Romeo, E., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0067-3 · Cited by 260
Preclinical development of a microRNA-based therapy for intervertebral disc degeneration
Ji, M.-L., Jiang, H., Zhang, X.-J., Shi, P.-L., Li, C., Wu, H., Wu, X.-T., Wang, Y.-T., Wang, C., & Lu, J. (2018) · Nature Communications · doi:10.1038/s41467-018-07360-1 · Cited by 259
Lekka, E., & Hall, J. (2018) · FEBS Letters · doi:10.1002/1873-3468.13182 · Cited by 251
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Long Noncoding RNA EBF3-AS Promotes Neuron Apoptosis in Alzheimer's Disease
Gu, C., Chen, C., Wu, R., Dong, T., Hu, X., Yao, Y., & Zhang, Y. (2018) · DNA and Cell Biology · doi:10.1089/dna.2017.4012 · Cited by 101
Rho/ROCK Pathway and Noncoding RNAs: Implications in Ischemic Stroke and Spinal Cord Injury
Kimura, T., Horikoshi, Y., Kuriyagawa, C., & Niiyama, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111573 · Cited by 55
Breast Cancer and the Other Non-Coding RNAs
Dvorská, D., Braný, D., Ňachajová, M., Halašová, E., & Danková, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063280 · Cited by 38
The regulatory role of miRNAs on VDR in breast cancer
Singh, T., & Adams, B. D. (2017) · Transcription · doi:10.1080/21541264.2017.1317695 · Cited by 37
“miRNAs are transcribed as primary miRNAs in the nucleus of the cell, and are enzymatically processed in the nucleus by a family of RNAseIII enzymes including DROSHA and AGO2.(78,1,2) The residual 85-nt hairpin structures termed pre-miRNAs are exported into the cytoplasm.”
BackgroundSelf-citation
Metadata
- Authors
- Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-03-01
- Volume
- 127
- Issue
- 3
- Pages
- 761-771
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2594574412
- Cited by
- 673
- References
- 139
- FWCI
- 32.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.